Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
CASyM. CASyM and the road to Systems Medicine; 2015.
BR Iyengar, 2015, Experimentation Can Enable Precision Medicine, Science, 350, 282
O Wolkenhauer, 2014, Enabling multiscale modeling in systems medicine, Genome Medicine, 6, 4, 10.1186/gm538
ARA Anderson, 2008, Integrative mathematical oncology, Nature Reviews Cancer, 8, 227, 10.1038/nrc2329
Z Agur, 2014, Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: Mathematics, statistics, and their integration, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 6, 239
JP Boissel, 2015, Bridging systems medicine and patient needs, CPT: Pharmacometrics and Systems Pharmacology, 4, 135
KK Giuliano, 2016, The urgent need for innovation in I.V. infusion devices, Nursing, 46, 66, 10.1097/01.NURSE.0000480617.62296.d7
DL Hertz, 2015, Pharmacogenetics of Cancer Drugs, Annual Review of Medicine, 66, 65, 10.1146/annurev-med-053013-053944
SE Jackson, 2015, Personalised cancer medicine, International Journal of Cancer, 137, 262, 10.1002/ijc.28940
A Paci, 2014, Review of therapeutic drug monitoring of anticancer drugs part 1—Cytotoxics, European Journal of Cancer, 50, 2010, 10.1016/j.ejca.2014.04.014
A Ballesta, 2017, Systems Chronotherapeutics, Pharmacological Reviews, 69, 161, 10.1124/pr.116.013441
F Lévi, 2007, Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, Advanced Drug Delivery Reviews, 59, 1015, 10.1016/j.addr.2006.11.001
R Dallmann, 2016, Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy, Trends in Molecular Medicine, 22, 430, 10.1016/j.molmed.2016.03.004
PF Innominato, 2010, Chronotherapy and the molecular clock: Clinical implications in oncology, Advanced Drug Delivery Reviews, 62, 979, 10.1016/j.addr.2010.06.002
F Levi, 2010, Circadian timing in cancer treatments, Annual review of pharmacology and toxicology, 50, 377, 10.1146/annurev.pharmtox.48.113006.094626
S Giacchetti, 2012, Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis, Annals of Oncology, 23, 3110, 10.1093/annonc/mds148
XM Li, 2013, A circadian clock transcription model for the personalization of cancer chronotherapy, Cancer Research, 73, 7176, 10.1158/0008-5472.CAN-13-1528
F Levi, 2017, Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metast, Annals of Oncology, 28, 10.1093/annonc/mdx393.048
E Ortiz-Tudela, 2016, Relevance of internal time and circadian robustness for cancer patients, BMC Cancer, 16, 10.1186/s12885-016-2319-9
F Lévi, 2016, Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study, Clinical Pharmacokinetics, 1
Evans LC, Society AM. Partial Differential Equations. Graduate studies in mathematics. American Mathematical Society; 1998. Available from: https://books.google.co.uk/books?id=5Pv4LVB_m8AC.
CR Culy, 2000, Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies, Drugs, 60, 895, 10.2165/00003495-200060040-00005
SP Joel, 2004, Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin, Clinical Pharmacology & Therapeutics, 76, 45, 10.1016/j.clpt.2004.03.008
RP Riechelmann, 2006, A systematic review on drug interactions in oncology, Cancer Investigation, 24, 704, 10.1080/07357900601063766
JN Vauthey, 2002, Body surface area and body weight predict total liver volume in western adults, Liver Transplantation, 8, 233, 10.1053/jlts.2002.31654
SB Nadler, 1962, Prediction of blood volume in normal human adults, Surgery, 51, 224
J Sendroy, 1966, Determination of human body volume from height and weight, Journal of Applied Physiology, 21, 167, 10.1152/jappl.1966.21.1.167
MA Graham, 2000, Clinical Pharmacokinetics of Oxaliplatin: A Critical Review, Clinical Cancer Research, 18, 1205
JG Slatter, 2000, Pharmacokinetics, Metabolism, and Excretion of Irinotecan (Cpt-11) following I. V. Infusion of [14C]Cpt-11 in Cancer Patients, Drug Metabolism and Disposition, 28, 423
BRL Schilsky, 1998, Biochemical and Clinical Pharmacology of 5-Fluorouracil Cellular Determinants of Sensitivity to Fluoropyrimidines, Oncology, 12, 13
NA Boughattas, 1989, Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice, Cancer Research, 49, 3362
D Wang, 2018, Human carboxylesterases: a comprehensive review, Acta Pharmaceutica Sinica B, 8, 699, 10.1016/j.apsb.2018.05.005
LP Rivory, 1996, Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase, Biochemical Pharmacology, 52, 1103, 10.1016/0006-2952(96)00457-1
Y Tsukamoto, 2001, A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU, Pharmaceutical Research, 18, 1190, 10.1023/A:1010939329562
O Combes, 2000, In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood, Investigational New Drugs, 18, 1, 10.1023/A:1006379730137
A Ballesta, 2011, A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery, PLoS Computational Biology, 7, 1, 10.1371/journal.pcbi.1002143
C Bertucci, 1995, The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation, Journal of pharmaceutical and biomedical analysis, 13, 1087, 10.1016/0731-7085(95)01548-Y
Pfizer. CAMPTOSAR (Irinotecan) HIGHLIGHTS OF PRESCRIBING INFORMATION; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf.
W Wang, 2007, On fuzzy cluster validity indices, Fuzzy Sets and Systems, 158, 2095, 10.1016/j.fss.2007.03.004
L Deyme, 2019, Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters, Cancer Chemotherapy and Pharmacology, 83, 27, 10.1007/s00280-018-3722-5
FA Lévi, 2016, Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV, Annals ofOncology, 27, 267, 10.1093/annonc/mdv548
F Lévi, 2017, Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228), British Journal of Cancer, 117, 965, 10.1038/bjc.2017.278
Jones E, Oliphant T, Peterson P, Others. {SciPy}: Open source scientific tools for {Python}; 2001. Available from: http://www.scipy.org/%22.
S Basu, 2016, Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1015-1016, 34, 10.1016/j.jchromb.2016.02.012
BN Matos, 2015, Development and Validation of a Simple and Selective Analytical HPLC Method for the Quantification of Oxaliplatin, Journal of Chemistry, 2015, 10.1155/2015/812701
M Munawar Hayat, 2019, Spectrophotometric determination of cisplatin, carboplatin and oxaliplatin in pure and injectable dosage forms, Biomedical Research, 30, 557, 10.35841/biomedicalresearch.30-19-244
Sendhoff B. Covariance Matrix Adaptation Revisited—the CMSA Evolution Strategy –. International Conference on Parallel Problem Solving from Nature. 2008;3242(Conference Paper · September 2008).
Xy Zhang, 2015, Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models, CPT: pharmacometrics & systems pharmacology, 4, 69
A Raue, 2009, Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood, Bioinformatics, 25, 1923, 10.1093/bioinformatics/btp358
D Kang, 2005, Sample Size Computations for PK / PD Population Models, Journal of Pharmacokinetics and Pharmacodynamics, 32, 685, 10.1007/s10928-005-0078-3
K Ogungbenro, 2010, Sample Size / Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements, Journal of Biopharmaceutical Statistics ISSN, 20, 1026, 10.1080/10543401003619205
F Pedregosa, 2011, Scikit-learn: Machine Learning in {P}ython, Journal of Machine Learning Research, 12, 2825